Rakovina Therapeutics Inc (V:RKV) — Market Cap & Net Worth
Market Cap & Net Worth: Rakovina Therapeutics Inc (RKV)
Rakovina Therapeutics Inc (V:RKV) has a market capitalization of $3.70 Million (CA$5.12 Million) as of September 16, 2026. Listed on the V stock exchange, this Canada-based company holds position #29228 globally and #1352 in its home market, demonstrating a 20.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rakovina Therapeutics Inc's stock price CA$0.27 by its total outstanding shares 21148039 (21.15 Million). Also see RKV total assets for a full breakdown of the balance sheet.
Rakovina Therapeutics Inc Market Cap History: 2021 to 2026
Rakovina Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows growth from $3.37 Million to $4.05 Million (1.07% CAGR). Also see RKV cash flow metrics for how efficiently the company converts equity into cash flow.
Rakovina Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rakovina Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Rakovina Therapeutics Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RKV by Market Capitalization
Companies near Rakovina Therapeutics Inc in the global market cap rankings as of September 16, 2026. Review RKV tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Rakovina Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Rakovina Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Rakovina Therapeutics Inc's market cap moved from $3.37 Million to $ 4.05 Million, with a yearly change of 1.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$4.05 Million | +165.00% |
| 2025 | CA$1.53 Million | -47.37% |
| 2024 | CA$2.91 Million | +123.53% |
| 2023 | CA$1.30 Million | -52.78% |
| 2022 | CA$2.75 Million | -18.18% |
| 2021 | CA$3.37 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Rakovina Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.70 Million USD |
| MoneyControl | $3.70 Million USD |
| MarketWatch | $3.70 Million USD |
| marketcap.company | $3.70 Million USD |
| Reuters | $3.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more